Free Trial
LON:ORPH

Open Orphan (ORPH) Share Price, News & Analysis

Open Orphan logo

About Open Orphan Stock (LON:ORPH)

Key Stats

Today's Range
N/A
50-Day Range
10
10
52-Week Range
N/A
Volume
652,639 shs
Average Volume
1.56 million shs
Market Capitalization
£67.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Open Orphan Plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers. The Disease in Motion platform has various potential applications across a range of end users, including big technology, wearables, pharma, and biotech companies. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; and biometry, data management, and statistics to its various European pharmaceutical clients, as well as drug development consultancy and services, including CMC (chemistry, manufacturing, and controls), and PK and medical writing to a range of European clients. The company is headquartered in London, the United Kingdom.

Receive ORPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Open Orphan and its competitors with MarketBeat's FREE daily newsletter.

ORPH Stock News Headlines

Sell NVDA Now?
Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.
See More Headlines

ORPH Stock Analysis - Frequently Asked Questions

Shares of ORPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Open Orphan investors own include HSBC (HSBA), Royal Dutch Shell (RDSB), Cassava Sciences (SAVA), Barclays (BARC), EQTEC (EQT), Grafton Group (GFTU) and Lloyds Banking Group (LLOY).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
179
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£34.71 million
Book Value
GBX 3.10 per share

Miscellaneous

Free Float
N/A
Market Cap
£67.09 million
Optionable
Not Optionable
Beta
N/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (LON:ORPH) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners